Exact Mass: 491.36105440000006
Exact Mass Matches: 491.36105440000006
Found 136 metabolites which its exact mass value is equals to given mass value 491.36105440000006,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
(7E,10E,13E,16E)-3-Hydroxydocosa-7,10,13,16-tetraenoylcarnitine
C29H49NO5 (491.36105440000006)
(7E,10E,13E,16E)-3-Hydroxydocosa-7,10,13,16-tetraenoylcarnitine is an acylcarnitine. More specifically, it is an (7E,10E,13E,16E)-3-hydroxydocosa-7,10,13,16-tetraenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (7E,10E,13E,16E)-3-Hydroxydocosa-7,10,13,16-tetraenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (7E,10E,13E,16E)-3-Hydroxydocosa-7,10,13,16-tetraenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(7Z,10Z,13E)-Tricosa-7,10,13-trienoylcarnitine
C30H53NO4 (491.39743780000003)
(7Z,10Z,13E)-Tricosa-7,10,13-trienoylcarnitine is an acylcarnitine. More specifically, it is an (7Z,10Z,13E)-tricosa-7,10,13-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (7Z,10Z,13E)-Tricosa-7,10,13-trienoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (7Z,10Z,13E)-Tricosa-7,10,13-trienoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(13Z,16Z,19Z)-Tricosa-13,16,19-trienoylcarnitine
C30H53NO4 (491.39743780000003)
(13Z,16Z,19Z)-Tricosa-13,16,19-trienoylcarnitine is an acylcarnitine. More specifically, it is an (13Z,16Z,19Z)-tricosa-13,16,19-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (13Z,16Z,19Z)-Tricosa-13,16,19-trienoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (13Z,16Z,19Z)-Tricosa-13,16,19-trienoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(10E)-11-(3,4-Dimethyl-5-pentylfuran-2-yl)undec-10-enoylcarnitine
C29H49NO5 (491.36105440000006)
(10E)-11-(3,4-dimethyl-5-pentylfuran-2-yl)undec-10-enoylcarnitine is an acylcarnitine. More specifically, it is an (10E)-11-(3,4-dimethyl-5-pentylfuran-2-yl)undec-10-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (10E)-11-(3,4-dimethyl-5-pentylfuran-2-yl)undec-10-enoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (10E)-11-(3,4-dimethyl-5-pentylfuran-2-yl)undec-10-enoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
11-{3,4-Dimethyl-5-[(1E)-pent-1-en-1-yl]furan-2-yl}undecanoylcarnitine
C29H49NO5 (491.36105440000006)
11-{3,4-dimethyl-5-[(1E)-pent-1-en-1-yl]furan-2-yl}undecanoylcarnitine is an acylcarnitine. More specifically, it is an 11-{3,4-dimethyl-5-[(1E)-pent-1-en-1-yl]furan-2-yl}undecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 11-{3,4-dimethyl-5-[(1E)-pent-1-en-1-yl]furan-2-yl}undecanoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine 11-{3,4-dimethyl-5-[(1E)-pent-1-en-1-yl]furan-2-yl}undecanoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Chenodeoxycholylvaline
C29H49NO5 (491.36105440000006)
Chenodeoxycholylvaline belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Chenodeoxycholylvaline consists of the bile acid chenodeoxycholic acid conjugated to the amino acid Valine conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Chenodeoxycholylvaline, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Chenodeoxycholylvaline appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).
Deoxycholylvaline
C29H49NO5 (491.36105440000006)
Deoxycholylvaline belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Deoxycholylvaline consists of the bile acid deoxycholic acid conjugated to the amino acid Valine conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Deoxycholylvaline, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Deoxycholylvaline appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).
Lipstatin
C29H49NO5 (491.36105440000006)
3beta-hydroxy-(22E,24R)-ergosta-5,8(14),22-triene-1,2-dicarboxylic acid imide|ergosterimide
Valine conjugated chenodeoxycholic acid
C29H49NO5 (491.36105440000006)
(3-docosanoyloxy-2-hydroxypropyl)-trimethylazanium,chloride
2,2,5,5-Tetramethyl-1-((11-(Triethoxysilyl)Undecyl)Oxy)-1,2,5-Azadisilolidine
C23H53NO4Si3 (491.32822180000005)
(7Z,10Z,13E)-Tricosa-7,10,13-trienoylcarnitine
C30H53NO4 (491.39743780000003)
(13Z,16Z,19Z)-Tricosa-13,16,19-trienoylcarnitine
C30H53NO4 (491.39743780000003)
(7E,10E,13E,16E)-3-Hydroxydocosa-7,10,13,16-tetraenoylcarnitine
C29H49NO5 (491.36105440000006)
(10E)-11-(3,4-Dimethyl-5-pentylfuran-2-yl)undec-10-enoylcarnitine
C29H49NO5 (491.36105440000006)
11-{3,4-Dimethyl-5-[(1E)-pent-1-en-1-yl]furan-2-yl}undecanoylcarnitine
C29H49NO5 (491.36105440000006)
3-[4-[(8R,9R,10R)-10-(hydroxymethyl)-6-(4-oxanylmethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]-N,N-dimethylbenzamide
C30H41N3O3 (491.3147756000001)
3-[4-[(8R,9R,10S)-10-(hydroxymethyl)-6-(4-oxanylmethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]-N,N-dimethylbenzamide
C30H41N3O3 (491.3147756000001)
3-[4-[(8S,9S,10S)-10-(hydroxymethyl)-6-(4-oxanylmethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]-N,N-dimethylbenzamide
C30H41N3O3 (491.3147756000001)
3-[4-[(8S,9R,10R)-10-(hydroxymethyl)-6-(4-oxanylmethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]-N,N-dimethylbenzamide
C30H41N3O3 (491.3147756000001)
4-[4-[(8R,9S,10R)-10-(hydroxymethyl)-6-(4-oxanylmethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]-N,N-dimethylbenzamide
C30H41N3O3 (491.3147756000001)
3-[4-[(8S,9S,10R)-10-(hydroxymethyl)-6-(4-oxanylmethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]-N,N-dimethylbenzamide
C30H41N3O3 (491.3147756000001)
3-[4-[(8R,9S,10R)-10-(hydroxymethyl)-6-(4-oxanylmethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]-N,N-dimethylbenzamide
C30H41N3O3 (491.3147756000001)
3-[4-[(8R,9S,10S)-10-(hydroxymethyl)-6-(4-oxanylmethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]-N,N-dimethylbenzamide
C30H41N3O3 (491.3147756000001)
3-[4-[(8S,9R,10S)-10-(hydroxymethyl)-6-(4-oxanylmethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]-N,N-dimethylbenzamide
C30H41N3O3 (491.3147756000001)
[3-[(9Z,12Z)-heptadeca-9,12-dienoxy]-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C25H50NO6P (491.33755700000006)
2-aminoethyl [2-hydroxy-3-[(11Z,14Z)-icosa-11,14-dienoxy]propyl] hydrogen phosphate
C25H50NO6P (491.33755700000006)
(E)-3-hydroxy-2-(2-hydroxydodecanoylamino)tridec-4-ene-1-sulfonic acid
C25H49NO6S (491.3280414000001)
3-hydroxy-2-[[(Z)-2-hydroxytetradec-9-enoyl]amino]undecane-1-sulfonic acid
C25H49NO6S (491.3280414000001)
(E)-3-hydroxy-2-(2-hydroxytridecanoylamino)dodec-4-ene-1-sulfonic acid
C25H49NO6S (491.3280414000001)
3-hydroxy-2-[[(Z)-2-hydroxytridec-8-enoyl]amino]dodecane-1-sulfonic acid
C25H49NO6S (491.3280414000001)
3-hydroxy-2-[[(Z)-2-hydroxydodec-5-enoyl]amino]tridecane-1-sulfonic acid
C25H49NO6S (491.3280414000001)
3-hydroxy-2-[[(Z)-2-hydroxypentadec-9-enoyl]amino]decane-1-sulfonic acid
C25H49NO6S (491.3280414000001)
(E)-3-hydroxy-2-(2-hydroxytetradecanoylamino)undec-4-ene-1-sulfonic acid
C25H49NO6S (491.3280414000001)
(E)-3-hydroxy-2-(2-hydroxypentadecanoylamino)dec-4-ene-1-sulfonic acid
C25H49NO6S (491.3280414000001)
2-(Decanoylamino)-3-hydroxyhexadecane-1-sulfonic acid
C26H53NO5S (491.36442480000005)
3-Hydroxy-2-(undecanoylamino)pentadecane-1-sulfonic acid
C26H53NO5S (491.36442480000005)
3-Hydroxy-2-(tetradecanoylamino)dodecane-1-sulfonic acid
C26H53NO5S (491.36442480000005)
2-(Dodecanoylamino)-3-hydroxytetradecane-1-sulfonic acid
C26H53NO5S (491.36442480000005)
3-Hydroxy-2-(pentadecanoylamino)undecane-1-sulfonic acid
C26H53NO5S (491.36442480000005)
2-(Hexadecanoylamino)-3-hydroxydecane-1-sulfonic acid
C26H53NO5S (491.36442480000005)
3-Hydroxy-2-(tridecanoylamino)tridecane-1-sulfonic acid
C26H53NO5S (491.36442480000005)
N-(decanoyl)-4E-pentadecasphingenine-1-phosphate
C25H50NO6P (491.33755700000006)
2-[[(4E,8E)-2-(heptanoylamino)-3-hydroxydodeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-(butanoylamino)-3-hydroxypentadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-acetamido-3-hydroxyheptadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-(pentanoylamino)tetradeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-(propanoylamino)hexadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-(hexanoylamino)-3-hydroxytrideca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
N-docosenoylsphingosine-1-phosphocholine
A sphingomyelin in which the total number of carbons in the fatty acyl group is 22 with 1 double bond.
(2e,4e,6e,8e,10e,12r,13r,14e,16s)-13-hydroxy-n-[(2s)-1-hydroxypropan-2-yl]-2,10,12,14,16-pentamethyl-18-phenyloctadeca-2,4,6,8,10,14-hexaenimidic acid
1,1,4a,8-tetramethyl-7-{2-[2-(methylamino)ethoxy]-2-oxoethylidene}-9-oxo-decahydrophenanthren-2-yl 3-hydroxy-3-methylbutanoate
(2s,4ar,4bs,7e,8r,8as,10ar)-1,1,4a,8-tetramethyl-7-{2-[2-(methylamino)ethoxy]-2-oxoethylidene}-9-oxo-decahydrophenanthren-2-yl 3-hydroxy-3-methylbutanoate
n-[(2s)-1-{[(2s,4e,7e)-1-(3-hexyl-4-oxooxetan-2-yl)trideca-4,7-dien-2-yl]oxy}-3-methyl-1-oxopentan-2-yl]carboximidic acid
C29H49NO5 (491.36105440000006)
1-[(1s,3as,3br,5as,7s,9as,9bs,11ar)-3a-hydroxy-7-{[(2r,4s,5r,6r)-4-methoxy-6-methyl-5-(methylamino)oxan-2-yl]oxy}-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]ethanone
C29H49NO5 (491.36105440000006)
n-[(2s)-1-{[(2s,4z,7z)-1-[(2s,3s)-3-hexyl-4-oxooxetan-2-yl]trideca-4,7-dien-2-yl]oxy}-4-methyl-1-oxopentan-2-yl]carboximidic acid
C29H49NO5 (491.36105440000006)
(3z,5e,7e,9e,11r,12s,13z,15e,17e,19e,21e,24s)-5,11,17,21,24-pentamethyl-3-(2-methylpropyl)-1-azacyclotetracosa-1,3,5,7,9,13,15,17,19,21-decaene-2,11,12-triol
(8e,10e)-13-hydroxy-n-(1-hydroxypropan-2-yl)-2,10,12,14,16-pentamethyl-18-phenyloctadeca-2,4,6,8,10,14-hexaenimidic acid
n-[(2s)-1-{[(2s,4e,7e)-1-(3-hexyl-4-oxooxetan-2-yl)trideca-4,7-dien-2-yl]oxy}-4-methyl-1-oxopentan-2-yl]carboximidic acid
C29H49NO5 (491.36105440000006)
(1s,2r,3r,4s,5r,6s,8s,9s,10r,13s,16s,17r)-8-ethoxy-11-ethyl-6,16-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate
(6e,8e,10e)-13-hydroxy-n-(1-hydroxypropan-2-yl)-2,10,12,14,16-pentamethyl-18-phenyloctadeca-2,4,6,8,10,14-hexaenimidic acid
(1s,5s,8r,12r,15r,16r,20s)-13-[(2r,3e,5r)-5,6-dimethylhept-3-en-2-yl]-5,19-dihydroxy-8,12-dimethyl-18-azahexacyclo[10.8.2.0³,⁸.0⁹,²¹.0¹⁵,²².0¹⁶,²⁰]docosa-2,18,21-trien-17-one
(2r,3r,4s,5r,6s,8s,9s,10r,13s,16s,17r)-8-ethoxy-11-ethyl-6,16-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate
n-(1-{[1-(3-hexyl-4-oxooxetan-2-yl)trideca-4,7-dien-2-yl]oxy}-4-methyl-1-oxopentan-2-yl)carboximidic acid
C29H49NO5 (491.36105440000006)
8-ethoxy-11-ethyl-6,16-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate
(2e,4e,6z,8e,10e,14e)-13-hydroxy-n-(1-hydroxypropan-2-yl)-2,10,12,14,16-pentamethyl-18-phenyloctadeca-2,4,6,8,10,14-hexaenimidic acid
1-[(1s,3s,3as,3br,7s,9ar,9bs,11ar)-7-{[(2r,4s,5r,6r)-5-amino-4-methoxy-6-methyloxan-2-yl]oxy}-3,3a-dihydroxy-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethanone
(2e,4z,6e,8e,10e,12r,13r,14e,16s)-13-hydroxy-n-[(2s)-1-hydroxypropan-2-yl]-2,10,12,14,16-pentamethyl-18-phenyloctadeca-2,4,6,8,10,14-hexaenimidic acid
(2e,4e,6z,8e,10e,12r,13r,14e,16s)-13-hydroxy-n-[(2s)-1-hydroxypropan-2-yl]-2,10,12,14,16-pentamethyl-18-phenyloctadeca-2,4,6,8,10,14-hexaenimidic acid
13-(5,6-dimethylhept-3-en-2-yl)-5,19-dihydroxy-8,12-dimethyl-18-azahexacyclo[10.8.2.0³,⁸.0⁹,²¹.0¹⁵,²².0¹⁶,²⁰]docosa-2,18,21-trien-17-one
1-{7-[(5-amino-4-methoxy-6-methyloxan-2-yl)oxy]-3,3a-dihydroxy-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}ethanone
1-[(1r,3as,3br,5as,7s,9as,9bs,11ar)-3a-hydroxy-7-{[(2r,4s,5r,6r)-4-methoxy-6-methyl-5-(methylamino)oxan-2-yl]oxy}-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]ethanone
C29H49NO5 (491.36105440000006)
13-hydroxy-n-(1-hydroxypropan-2-yl)-2,10,12,14,16-pentamethyl-18-phenyloctadeca-2,4,6,8,10,14-hexaenimidic acid
(1s,5s,8r,9r,12r,13r,15r,16r,20s)-13-[(2r,3e,5r)-5,6-dimethylhept-3-en-2-yl]-5,19-dihydroxy-8,12-dimethyl-18-azahexacyclo[10.8.2.0³,⁸.0⁹,²¹.0¹⁵,²².0¹⁶,²⁰]docosa-2,18,21-trien-17-one
1-(3a-hydroxy-7-{[4-methoxy-6-methyl-5-(methylamino)oxan-2-yl]oxy}-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl)ethanone
C29H49NO5 (491.36105440000006)